UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000000478
Receipt number R000000578
Scientific Title Preventive effect of frozen glove for docetaxel-induced nail toxicities in advanced breast cancer patients
Date of disclosure of the study information 2006/09/11
Last modified on 2016/02/24 16:13:05

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Preventive effect of frozen glove for docetaxel-induced nail toxicities in advanced breast cancer patients

Acronym

Effect of frozen glove for prevention of docetaxel-induced nail toxicities

Scientific Title

Preventive effect of frozen glove for docetaxel-induced nail toxicities in advanced breast cancer patients

Scientific Title:Acronym

Effect of frozen glove for prevention of docetaxel-induced nail toxicities

Region

Japan


Condition

Condition

Breast cancer

Classification by specialty

Hematology and clinical oncology

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

Analysis of preventive effect of frozen glove for Docetaxel-induced nail toxicities when used as standard method (frozen @-30C for longer than 3 hours, apply 15 minutes prior to docetaxel infusion and change to new glove after 45 minutes) versus simpler method for advanced breast cancer patients

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1

Confirmatory

Trial characteristics_2

Pragmatic

Developmental phase

Phase II


Assessment

Primary outcomes

Occurrence of any nail toxicities at 4 months of Docetaxel infusion

Key secondary outcomes

Occurrence of any grade 2 or higher nail toxicities at 4 months of Docetaxel infusion
Time (and total number or amount of Docetaxel administration) until first occurrence of any Docetaxel-induced nail toxicities
Detail classification of grade 2 or higher nail toxicities
Degree of un-comfort by the use of frozen glove


Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Active

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Treatment

Type of intervention

Device,equipment

Interventions/Control_1

Simpler freezing method and shorter administration of frozen glove in experimental side (hand)

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

69 years-old >=

Gender

Female

Key inclusion criteria

Female with pathologically proven breast cancer
Clinical stage 4(TNM) or incurable recurrent breast cancer
PS(ECOG) 0~2
Docetaxel administration 40mg/m2 planed at least more than once a month (before 1st administration)
Preserved major organ function
Written informed consent

Key exclusion criteria

Infection, Fever = or > 38C
Serious comorbidity
Interstitial pneumonitis/fibrosis
Peripheral neuropathy/edema
Raynaud symptom/peripheral arterial disease
Finger skin/bone/soft tissue metastasis
Positive HBsAg
Apparent nail adverse effect
Decision by primary physician

Target sample size

25


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Hiroshi Ishiguro, MD, PhD

Organization

Kyoto University Hospital

Division name

Outpatient Oncology Unit

Zip code


Address

54 Shogoinkawahara-cho, Sakyo-ku, Kyoto, Japan 606-8507

TEL


Email



Public contact

Name of contact person

1st name
Middle name
Last name

Organization

Kyoto University Hospital

Division name

Outpatient Oncology Unit

Zip code


Address


TEL


Homepage URL


Email

oncolctr@kuhp.kyoto-u.ac.jp


Sponsor or person

Institute

Outpatient Oncology Unit
Kyoto University Hospital

Institute

Department

Personal name



Funding Source

Organization

none

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

YES

Study ID_1

C79

Org. issuing International ID_1

Kyoto University, Ethical Review Board

Study ID_2

TCO-0604

Org. issuing International ID_2

Kyoto University Hospital, Outpatient Oncology Unit

IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2006 Year 09 Month 11 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2006 Year 11 Month 30 Day

Date of IRB


Anticipated trial start date

2006 Year 12 Month 01 Day

Last follow-up date

2011 Year 01 Month 01 Day

Date of closure to data entry

2011 Year 01 Month 01 Day

Date trial data considered complete

2011 Year 02 Month 01 Day

Date analysis concluded

2011 Year 02 Month 01 Day


Other

Other related information



Management information

Registered date

2006 Year 08 Month 28 Day

Last modified on

2016 Year 02 Month 24 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000000578


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name